Response to ASX Aware Letter

• ACL reaffirmed its FY25 guidance on multiple occasions
• Analyst forecasts were within ACL's guidance range
• ACL did not expect the release of its results to have a material effect on its share price

Australian Clinical Labs (ACL) has responded to an ASX Aware Letter, providing details on its earnings performance and guidance for the half year ended 31 December 2024. ACL stated that it does not consider any measure of its statutory or underlying earnings for the period differed materially from market expectations, based on its previously issued guidance and analyst forecasts. Specifically, ACL noted that it had provided guidance for FY25 revenue of $725M-$752M and underlying EBIT of $65M-$73M, which it reaffirmed on multiple occasions leading up to the results release. Additionally, ACL reviewed sell-side analyst reports and confirmed that all forecasts were within its guidance range. Given this, ACL did not expect the release of its half year results to have a material effect on its share price. ACL confirmed that it is in compliance with its continuous disclosure obligations under the Listing Rules and that its responses have been approved by its Disclosure Committee.

ACL reaffirmed its FY25 guidance of revenue of $725M to $752M and underlying EBIT of $65M to $73M.